keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed b-cell lymphoma

keyword
https://read.qxmd.com/read/30757910/evaluation-of-treatment-patterns-and-survival-among-patients-with-diffuse-large-b-cell-lymphoma-in-the-usa
#1
Vicki A Morrison, Yaping Shou, Jill A Bell, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Michael Eaddy, Aaron Galaznik
AIM: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL). PATIENTS & METHODS: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated. RESULTS: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). Patients who received monotherapy were older with more comorbidities and had shorter progression-free survival than patients receiving combination therapy (median, 31...
February 13, 2019: Future Oncology
https://read.qxmd.com/read/30756407/dimethyl-fumarate-a-two-edged-drug-current-status-and-future-directions
#2
REVIEW
Nathaniel Edward Bennett Saidu, Niloufar Kavian, Karen Leroy, Claus Jacob, Carole Nicco, Frédéric Batteux, Jérôme Alexandre
Dimethyl fumarate (DMF) is a fumaric acid ester registered for the treatment of relapsing-remitting multiple sclerosis (RRMS). It induces protein succination leading to inactivation of cysteine-rich proteins. It was first shown to possess cytoprotective and antioxidant effects in noncancer models, which appeared related to the induction of the nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) pathway. DMF also displays antitumor activity in several cellular and mice models. Recently, we showed that the anticancer mechanism of DMF is dose-dependent and is paradoxically related to the decrease in the nuclear translocation of NRF2...
February 12, 2019: Medicinal Research Reviews
https://read.qxmd.com/read/30755239/human-bone-marrow-derived-mesenchymal-stem-cells-promote-the-growth-and-drug-resistance-of-diffuse-large-b-cell-lymphoma-by-secreting-il-6-and-elevating-il-17a-levels
#3
Weijie Zhong, Zhigang Zhu, Xin Xu, Hui Zhang, Huabao Xiong, Qingshan Li, Yaming Wei
BACKGROUND: The drug-resistance and relapse of diffuse large B-cell lymphoma (DLBCL), which are related to mesenchymal stem cells (MSCs), have become increasingly common. However, the underlying mechanisms remain elusive. METHODS: CCK 8 assay, colony formation assay, and xenograft mouse model were used to investigate the effects of hBMSCs on DLBCL growth. Immunohistochemistry, qRT-PCR, and ELISA were used to study the expressions of IL-6 and IL-17A. Flow cytometry was used to analyze Th17 cells and Treg cells expressions...
February 12, 2019: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/30745556/-recurrence-of-malignant-lymphoma-immediately-after-treatment-for-hepatitis-c-virus-using-direct-acting-antivirals
#4
Kosuke Iwane, Takahisa Kayahara, Hiroyuki Takabatake, Yoichi Morimoto, Akiko Iseki, Motowo Mizuno, Kenji Notohara
A Japanese male in his 70s with chronic hepatitis C was diagnosed with diffuse large B-cell lymphoma and achieved and maintained complete remission following treatment with eight cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisolone). Seven years later, he received the direct-acting antivirals (DAAs) sofosbuvir/ledipasvir for hepatitis C virus (HCV) genotype 1b. Although the patient achieved sustained virological response immediately after the initial treatment period, laboratory data showed elevation of LD and soluble IL-2R...
2019: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://read.qxmd.com/read/30742566/dynamo-a-phase-ii-study-of-duvelisib-ipi-145-in-patients-with-refractory-indolent-non-hodgkin-lymphoma
#5
Ian W Flinn, Carole B Miller, Kirit M Ardeshna, Scott Tetreault, Sarit E Assouline, Jiri Mayer, Michele Merli, Scott D Lunin, Andrew R Pettitt, Zoltan Nagy, Olivier Tournilhac, Karem-Etienne Abou-Nassar, Michael Crump, Eric D Jacobsen, Sven de Vos, Virginia M Kelly, Weiliang Shi, Lori Steelman, NgocDiep Le, David T Weaver, Stephanie Lustgarten, Nina D Wagner-Johnston, Pier Luigi Zinzani
PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy...
February 11, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/30741017/primary-neurolymphomatosis-of-the-trigeminal-nerve
#6
Hirotaka Sato, Satoru Hiroshima, Ryogo Anei, Kyousuke Kamada
We report a case of a primary malignant lymphoma of the trigeminal nerve that was associated with facial pain. A 65-year-old man was examined at another hospital for unilateral facial pain. Carbamazepine was prescribed, but his symptoms did not improve. Magnetic resonance imaging (MRI) revealed swelling of the trigeminal nerve and a mass lesion in Meckel's cave. The patient was referred to our hospital at this point. Gadolinium-enhanced MRI and F18-Fluorodeoxyglucose-position emission tomography suggested a likely malignant tumour and a biopsy was performed...
February 11, 2019: British Journal of Neurosurgery
https://read.qxmd.com/read/30740662/biology-and-therapy-of-primary-mediastinal-b-cell-lymphoma-current-status-and-future-directions
#7
REVIEW
Charlotte Lees, Colm Keane, Maher K Gandhi, Jay Gunawardana
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Nuclear factor kappa B (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathways are characteristically dysregulated in PMBCL and implicated in several aspects of disease pathogenesis, and the latter pathway in host immune evasion...
February 10, 2019: British Journal of Haematology
https://read.qxmd.com/read/30740656/optimizing-outcomes-for-children-with-non-hodgkin-lymphoma-in-low-and-middle-income-countries-by-early-correct-diagnosis-reducing-toxic-death-and-preventing-abandonment
#8
REVIEW
Guillermo Chantada, Catherine G Lam, Scott C Howard
In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low- and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens...
February 10, 2019: British Journal of Haematology
https://read.qxmd.com/read/30733909/relapsing-long-lasting-garcin-syndrome-revealing-skull-base-diffuse-b-cell-lymphoma-the-diagnosis-through-the-hartel-s-route
#9
Barbara Casolla, Serena Candela, Antonio Ciacciarelli, Ludovico Ciolli, Andrea Romano, Michele Acqui, Maria Christina Cox, Giuliano Sette, Francesco Orzi
The Garcin syndrome is a rare condition characterized by multiple unilateral cranial nerve palsy, without neither long-tract involvement nor intracranial hypertension. Non-Hodgkin lymphoma is a systemic malignant disease that localizes in a minority of cases in the central nervous system. We report a case of Garcin syndrome that revealed a diffuse large B cell lymphoma (DLBCL) located in the skull base and in the right kidney. We reached the diagnosis by mean of a nonstandard, mini-invasive, transforamen ovale biopsy of the intracranial lesion (Hartel's route)...
February 2019: Journal of Neurological Surgery. Part B, Skull Base
https://read.qxmd.com/read/30733632/diffuse-large-b-cell-lymphoma-relapsing-in-leukaemic-phase-presenting-as-acute-leukaemia
#10
Priyavadhana Balasubramanian, Prashant Ramteke, Saumyaranjan Mallick, Lalit Kumar, Pranay Tanwar
Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of the newly diagnosed adult non-Hodgkin lymphomas, but rarely presents in leukaemic phase. Here in, we report a case of DLBCL presenting in leukaemic phase and masquerading as acute leukaemia. A 28-year-old woman presented to our outpatient department with complaints of fever for 1 week. Her peripheral blood smear showed 5% to 8% blasts. Bone marrow aspirate showed an infiltration by ~30% blasts. Flow cytometry and immunohistochemistry confirmed relapse of DLBCL...
2019: Clinical Medicine Insights. Blood Disorders
https://read.qxmd.com/read/30723112/-myd88-l265p-mutation-and-cdkn2a-loss-are-early-mutational-events-in-primary-central-nervous-system-diffuse-large-b-cell-lymphomas
#11
Naema Nayyar, Michael D White, Corey M Gill, Matthew Lastrapes, Mia Bertalan, Alexander Kaplan, Megan R D'Andrea, Ivanna Bihun, Andrew Kaneb, Jorg Dietrich, Judith A Ferry, Maria Martinez-Lage, Anita Giobbie-Hurder, Darrell R Borger, Fausto J Rodriguez, Matthew P Frosch, Emily Batchelor, Kaitlin Hoang, Benjamin Kuter, Sarah Fortin, Matthias Holdhoff, Daniel P Cahill, Scott Carter, Priscilla K Brastianos, Tracy T Batchelor
The genetic alterations that define primary central nervous system lymphoma (PCNSL) are incompletely elucidated, and the genomic evolution from diagnosis to relapse is poorly understood. We performed whole-exome sequencing (WES) on 36 PCNSL patients and targeted MYD88 sequencing on a validation cohort of 27 PCNSL patients. We also performed WES and phylogenetic analysis of 3 matched newly diagnosed and relapsed tumor specimens and 1 synchronous intracranial and extracranial relapse. Immunohistochemistry (IHC) for programmed death-1 ligand (PD-L1) was performed on 43 patient specimens...
February 12, 2019: Blood Advances
https://read.qxmd.com/read/30723110/ptcy-based-haploidentical-vs-matched-related-or-unrelated-donor-reduced-intensity-conditioning-transplant-for-dlbcl
#12
Peter Dreger, Anna Sureda, Kwang Woo Ahn, Mary Eapen, Carlos Litovich, Herve Finel, Ariane Boumendil, Ajay Gopal, Alex F Herrera, Christoph Schmid, José Luis Diez-Martin, Ephraim Fuchs, Javier Bolaños-Meade, Mahasweta Gooptu, Monzr M Al Malki, Luca Castagna, Stefan O Ciurea, Alida Dominietto, Didier Blaise, Fabio Ciceri, Johanna Tischer, Paolo Corradini, Silvia Montoto, Stephen Robinson, Zafer Gülbas, Mehdi Hamadani
This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included...
February 12, 2019: Blood Advances
https://read.qxmd.com/read/30719883/-ring-shaped-lesions-on-a-lung-scan
#13
Mustafa Coşkuntürk, Erik H J G Aarntzen, Walter J F M van der Velden
A 25-year-old man was treated with pembrolizumab for a relapsed-refractory primary mediastinal large B-cell lymphoma. On an evaluation PET-CT scan multiple 'reversed halo signs' were noticed. No infectious cause was established and we diagnosed the lesions as pembrolizumab-induced pneumonitis, an immune-related adverse event.
January 30, 2019: Nederlands Tijdschrift Voor Geneeskunde
https://read.qxmd.com/read/30719267/novel-treatment-approaches-and-future-perspectives-in-follicular-lymphoma
#14
REVIEW
Grerk Sutamtewagul, Brian K Link
Follicular lymphoma (FL) is a common B-cell malignancy characterized by relatively indolent growth and incurability with an expected lifetime course of serial intermittent treatment courses. Many patients with FL have lives shortened by the disease and despite a relatively favorable prognosis relative to other incurable systemic malignancies, optimal management of FL has not been achieved. This review focuses on identifying both patients for whom novel therapies might be most beneficial as well as systematically reviewing novel strategies at various levels of investigation...
2019: Therapeutic Advances in Hematology
https://read.qxmd.com/read/30716178/alopecic-patches-of-the-scalp-a-variant-of-primary-cutaneous-follicle-center-b-cell-lymphoma-reported-in-a-series-of-14-cases
#15
Adele de Masson, Jean-David Bouaziz, Caroline Ram-Wolff, Pauline Brice, Isabelle Moulonguet, Marie-Dominique Vignon-Pennamen, Florian Herms, Laurence Verneuil, Jacqueline Rivet, Martine Bagot, Maxime Battistella
Primary cutaneous follicle center lymphoma (PCFCL) is the most frequent primary cutaneous B-cell lymphoma. It presents usually with erythematous papules, plaques and tumors that predominate on the head, neck and upper trunk. The evolution is indolent but relapses are frequent. Atypical presentations of PCFCL have been occasionally described, such as diffuse facial erythema, one case of scarring alopecia (1), macular lesions, including 2 cases of scarring alopecia (2), miliary agminated papules (3), or extensive telangiectasia of the scalp (4)...
February 4, 2019: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/30715765/primary-cutaneous-large-b-cell-lymphomas-relevance-of-the-2017-who-classification
#16
Sarah Menguy, Marie Beylot-Barry, Parrens Marie, Anne Pham Ledard, Eric Frison, François Comoz, Maxime Battistella, Vanessa Szablewski, Brigitte Balme, Anne Croue, Frédéric Franck, Nicolas Ortonne, Emilie Tournier, Laurence Lamant, Agnès Carlotti, Anne De Muret, François Le Gall, Marie-Hélène Lorton, Jean-Philippe Merlio, Béatrice Vergier
AIMS: We applied the 2017 WHO classification criteria to categorize a series of 64 primary cutaneous large B-cell lymphomas (PCLBCLs), containing a majority (⩾80%) of large-cells and a proliferative rate ⩾40%, raising the problem of the differential diagnosis between PCLBCLs, leg type (PCLBCLs-LT) or primary cutaneous follicle center lymphomas with large cell morphology (PCFCLs-LC). The aims were to determine reproducibility and prognostic relevance of the 2017 WHO criteria. METHODS AND RESULTS: Morphology and phenotype identified 32 PCLBCLs-LT and 25 PCFCLs-LC; 7 cases (11%) remained unclassified...
February 4, 2019: Histopathology
https://read.qxmd.com/read/30709431/tolerability-and-activity-of-ublituximab-umbralisib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukaemia-and-non-hodgkin-lymphoma-a-phase-1-dose-escalation-and-expansion-trial
#17
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H Fowler
BACKGROUND: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies. METHODS: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Eligible patients were aged 18 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less...
February 2019: Lancet Haematology
https://read.qxmd.com/read/30702589/18f-fdg-pet-ct-for-staging-and-response-assessment-of-primary-parotid-malt-lymphoma-with-multiple-sites-involvement-a-case-report
#18
Yixuan Ren, Lele Huang, Yuping Han, Zhencun Cui, Jicheng Li, Chi Dong, Jiangyan Liu
RATIONALE: Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal low-grade B cell lymphoma that generally exhibits an indolent clinical course. Currently, the application of F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in MALT lymphoma is still controversial. Herein, we reported a case of using F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement. As far as we know, there are no similar case reports have been published before...
February 2019: Medicine (Baltimore)
https://read.qxmd.com/read/30702000/treatment-of-aggressive-b-cell-non-hodgkin-lymphoma-beyond-frontline-therapy-in-patients-not-eligible-for-stem-cell-transplantation-a-structured-review
#19
Gilles A Salles, Ruth Pettengell, Raul Cordoba, Monika Długosz-Danecka, Wojciech Jurczak, Hervé Tilly
Aggressive B-cell non-Hodgkin lymphoma (aNHL) accounts for ∼50% of all NHL cases. The only potentially curative, broadly available treatment for patients with relapse, failing frontline treatment, is high-dose therapy followed by autologous stem cell transplantation (ASCT); patients ineligible for/who have failed ASCT have limited standard-of-care options. We conducted a structured review of treatments for relapsed/refractory patients with aNHL based on literature published between 2006 and 2017. Of the 22 publications identified for inclusion, most described phase II, single-arm trials (N = 25-217), and only three were randomized studies (phase II [N = 96], phase II/III [N = 111] and phase III [N = 338])...
January 31, 2019: Leukemia & Lymphoma
https://read.qxmd.com/read/30701541/novel-targeted-therapeutic-agents-for-the-treatment-of-childhood-adolescent-and-young-adult-non-hodgkin-lymphoma
#20
REVIEW
Matthew J Barth, Veronique Minard-Colin
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies. Most NHLs in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi-agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long-term toxicity. However, in the rarer instance of relapsed or refractory disease, outcomes are dismal. Novel therapeutic approaches to the treatment of both T-cell and B-cell NHLs are critical to improve outcomes while also minimising the associated toxicity of current treatment regimes...
January 30, 2019: British Journal of Haematology
keyword
keyword
171524
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"